candesartan has been researched along with Angiogenesis, Pathologic in 16 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In this study, we evaluated the efficacy of the AT1R antagonist candesartan in bladder cancer." | 7.73 | Angiotensin II type 1 receptor antagonist candesartan as an angiogenic inhibitor in a xenograft model of bladder cancer. ( Horiguchi, Y; Kikuchi, E; Kosugi, M; Miyajima, A; Murai, M, 2006) |
| "Candesartan was able to reverse this process in a dose-dependent manner." | 5.43 | Candesartan attenuates angiogenesis in hepatocellular carcinoma via downregulating AT1R/VEGF pathway. ( Fan, F; Jiang, G; Liu, Z; Lu, Y; Shen, C; Tao, L; Tian, C; Wu, H, 2016) |
| " In this study, we evaluated the efficacy of the AT1R antagonist candesartan against bladder cancer." | 3.74 | Effect of angiotensin II type 1 receptor antagonist on tumor growth and angiogenesis in a xenograft model of human bladder cancer. ( Horiguchi, Y; Kikuchi, E; Kosaka, T; Kosugi, M; Miyajima, A; Murai, M, 2007) |
| "This study examined the potential role of Angiotensin II for the regulation of angiogenesis associated genes in receptor positive and negative human breast cancer." | 3.74 | Potential role of Renin-Angiotensin-system for tumor angiogenesis in receptor negative breast cancer. ( Fraser, HM; Hack, G; Herr, D; Konrad, R; Kreienberg, R; Rodewald, M; Wulff, C, 2008) |
| " In this study, we evaluated the efficacy of the AT1R antagonist candesartan in bladder cancer." | 3.73 | Angiotensin II type 1 receptor antagonist candesartan as an angiogenic inhibitor in a xenograft model of bladder cancer. ( Horiguchi, Y; Kikuchi, E; Kosugi, M; Miyajima, A; Murai, M, 2006) |
| "BACKGROUND Breast cancer is among the deadliest cancers across the world and is responsible for countless deaths." | 1.46 | Nano-Hydroxyapatite-Derived Drug and Gene Co-Delivery System for Anti-Angiogenesis Therapy of Breast Cancer. ( Chen, X; Liu, Y; Wang, Y; Zhao, L; Zhao, W, 2017) |
| "Candesartan was able to reverse this process in a dose-dependent manner." | 1.43 | Candesartan attenuates angiogenesis in hepatocellular carcinoma via downregulating AT1R/VEGF pathway. ( Fan, F; Jiang, G; Liu, Z; Lu, Y; Shen, C; Tao, L; Tian, C; Wu, H, 2016) |
| "The effect of ARBs on prostate cancer in experimental models compared with meta-analysis data from clinical trials is conflicting." | 1.40 | Clinically relevant doses of candesartan inhibit growth of prostate tumor xenografts in vivo through modulation of tumor angiogenesis. ( Al-Azayzih, A; Alhusban, A; Fagan, SC; Gao, F; Goc, A; Somanath, PR, 2014) |
| "A multifunctional copolymer-anticancer conjugate chitosan-graft-polyethyleneimine-candesartan (CPC) containing low molecular weight chitosan (CS) backbone and polyethyleneimine (PEI) arms with candesartan (CD) conjugated via an amide bond was fabricated as a targeted co-delivery nanovector of drug and gene for potential cancer therapy." | 1.40 | A chitosan-graft-PEI-candesartan conjugate for targeted co-delivery of drug and gene in anti-angiogenesis cancer therapy. ( Bao, X; Ding, Y; Jin, Y; Wang, C; Wang, W; Wang, X; Wang, Y; Zhou, J, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (56.25) | 29.6817 |
| 2010's | 7 (43.75) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ding, X | 1 |
| Su, Y | 1 |
| Wang, C | 2 |
| Zhang, F | 1 |
| Chen, K | 1 |
| Wang, Y | 3 |
| Li, M | 1 |
| Wang, W | 2 |
| Zhao, L | 1 |
| Zhao, W | 1 |
| Liu, Y | 1 |
| Chen, X | 1 |
| Alhusban, A | 1 |
| Al-Azayzih, A | 1 |
| Goc, A | 1 |
| Gao, F | 1 |
| Fagan, SC | 2 |
| Somanath, PR | 1 |
| Bao, X | 1 |
| Zhou, J | 1 |
| Ding, Y | 1 |
| Wang, X | 1 |
| Jin, Y | 1 |
| Shanab, AY | 1 |
| Elshaer, SL | 1 |
| El-Azab, MF | 1 |
| Soliman, S | 1 |
| Sabbineni, H | 1 |
| Matragoon, S | 1 |
| El-Remessy, AB | 1 |
| Fan, F | 1 |
| Tian, C | 1 |
| Tao, L | 1 |
| Wu, H | 1 |
| Liu, Z | 1 |
| Shen, C | 1 |
| Jiang, G | 1 |
| Lu, Y | 1 |
| Wasa, J | 1 |
| Sugiura, H | 1 |
| Kozawa, E | 1 |
| Kohyama, K | 1 |
| Yamada, K | 1 |
| Taguchi, O | 1 |
| Miyajima, A | 3 |
| Kosaka, T | 2 |
| Asano, T | 2 |
| Seta, K | 1 |
| Kawai, T | 1 |
| Hayakawa, M | 1 |
| Suganuma, T | 1 |
| Ino, K | 1 |
| Shibata, K | 1 |
| Kajiyama, H | 1 |
| Nagasaka, T | 1 |
| Mizutani, S | 1 |
| Kikkawa, F | 1 |
| Cazaubon, S | 1 |
| Deshayes, F | 1 |
| Couraud, PO | 1 |
| Nahmias, C | 1 |
| Kosugi, M | 2 |
| Kikuchi, E | 2 |
| Horiguchi, Y | 2 |
| Murai, M | 2 |
| Sugawara, A | 1 |
| Ito, S | 1 |
| Imai, N | 1 |
| Hashimoto, T | 1 |
| Kihara, M | 1 |
| Yoshida, S | 1 |
| Kawana, I | 1 |
| Yazawa, T | 1 |
| Kitamura, H | 1 |
| Umemura, S | 1 |
| Herr, D | 1 |
| Rodewald, M | 1 |
| Fraser, HM | 1 |
| Hack, G | 1 |
| Konrad, R | 1 |
| Kreienberg, R | 1 |
| Wulff, C | 1 |
| Tamarat, R | 1 |
| Silvestre, JS | 1 |
| Durie, M | 1 |
| Levy, BI | 1 |
2 reviews available for candesartan and Angiogenesis, Pathologic
| Article | Year |
|---|---|
[Endothelin-1, angiotensin II and cancer].
Topics: Angiogenesis Inhibitors; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Antineoplastic Age | 2006 |
[Stimulatory effects of angiotensin II on angiogenesis].
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; A | 2006 |
14 other studies available for candesartan and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Synergistic Suppression of Tumor Angiogenesis by the Co-delivering of Vascular Endothelial Growth Factor Targeted siRNA and Candesartan Mediated by Functionalized Carbon Nanovectors.
Topics: Animals; Benzimidazoles; Biphenyl Compounds; Cell Line, Tumor; Humans; Mice; Mice, Nude; Nanotubes, | 2017 |
Nano-Hydroxyapatite-Derived Drug and Gene Co-Delivery System for Anti-Angiogenesis Therapy of Breast Cancer.
Topics: Angiogenesis Inhibitors; Animals; Benzimidazoles; Biphenyl Compounds; Breast Neoplasms; Cell Line, T | 2017 |
Clinically relevant doses of candesartan inhibit growth of prostate tumor xenografts in vivo through modulation of tumor angiogenesis.
Topics: Angiogenesis Inhibitors; Animals; Benzimidazoles; Biphenyl Compounds; Cell Line, Tumor; Cell Movemen | 2014 |
A chitosan-graft-PEI-candesartan conjugate for targeted co-delivery of drug and gene in anti-angiogenesis cancer therapy.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Cell Line, Tum | 2014 |
Candesartan stimulates reparative angiogenesis in ischemic retinopathy model: role of hemeoxygenase-1 (HO-1).
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Gene Silencing | 2015 |
Candesartan attenuates angiogenesis in hepatocellular carcinoma via downregulating AT1R/VEGF pathway.
Topics: Angiogenesis Inhibitors; Angiotensin II; Animals; Benzimidazoles; Biphenyl Compounds; Carcinoma, Hep | 2016 |
The tumor suppressive effect of angiotensin II type 1 receptor antagonist in a murine osteosarcoma model.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Benzimidazoles; Biphenyl Compounds; Blo | 2011 |
Angiotensin II type I antagonist prevents pulmonary metastasis of murine renal cancer by inhibiting tumor angiogenesis.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Animals; Antineoplastic Agents; Benzimidazoles; Biphe | 2002 |
Functional expression of the angiotensin II type 1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumor invasion, angiogenesis, and peritoneal dissemination.
Topics: Adenocarcinoma; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antigens, CD34; Be | 2005 |
Angiotensin II type 1 receptor antagonist candesartan as an angiogenic inhibitor in a xenograft model of bladder cancer.
Topics: Aged; Angiogenesis Inhibitors; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Bip | 2006 |
Roles for host and tumor angiotensin II type 1 receptor in tumor growth and tumor-associated angiogenesis.
Topics: Adaptor Proteins, Signal Transducing; Analysis of Variance; Animals; Benzimidazoles; Biphenyl Compou | 2007 |
Effect of angiotensin II type 1 receptor antagonist on tumor growth and angiogenesis in a xenograft model of human bladder cancer.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Benz | 2007 |
Potential role of Renin-Angiotensin-system for tumor angiogenesis in receptor negative breast cancer.
Topics: Angiopoietin-1; Angiopoietin-2; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Basic Helix | 2008 |
Angiotensin II angiogenic effect in vivo involves vascular endothelial growth factor- and inflammation-related pathways.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antibodies, Monoclonal; Benzimidazoles; B | 2002 |